Platte River Wealth Advisors LLC Has $7.49 Million Holdings in Eli Lilly and Company (NYSE:LLY)

Platte River Wealth Advisors LLC decreased its position in Eli Lilly and Company (NYSE:LLY) by 2.3% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 8,272 shares of the company’s stock after selling 198 shares during the quarter. Eli Lilly and Company accounts for approximately 2.1% of Platte River Wealth Advisors LLC’s holdings, making the stock its 13th largest holding. Platte River Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $7,489,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of LLY. Everpar Advisors LLC bought a new stake in Eli Lilly and Company during the 4th quarter worth about $1,845,000. International Assets Investment Management LLC increased its position in shares of Eli Lilly and Company by 5.3% during the 4th quarter. International Assets Investment Management LLC now owns 12,597 shares of the company’s stock worth $7,343,000 after purchasing an additional 632 shares during the last quarter. Tennessee Valley Asset Management Partners bought a new stake in shares of Eli Lilly and Company during the 4th quarter worth approximately $181,000. Oliver Lagore Vanvalin Investment Group grew its stake in shares of Eli Lilly and Company by 27.7% in the fourth quarter. Oliver Lagore Vanvalin Investment Group now owns 387 shares of the company’s stock valued at $226,000 after buying an additional 84 shares in the last quarter. Finally, HTLF Bank bought a new stake in Eli Lilly and Company during the fourth quarter worth $444,000. 82.53% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 750 shares of Eli Lilly and Company stock in a transaction that occurred on Monday, June 3rd. The stock was sold at an average price of $819.47, for a total value of $614,602.50. Following the completion of the sale, the chief accounting officer now directly owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a filing with the SEC, which is available at the SEC website. In other news, CAO Donald A. Zakrowski sold 750 shares of the company’s stock in a transaction dated Monday, June 3rd. The shares were sold at an average price of $819.47, for a total transaction of $614,602.50. Following the transaction, the chief accounting officer now owns 7,130 shares in the company, valued at $5,842,821.10. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, major shareholder Lilly Endowment Inc sold 210,000 shares of the firm’s stock in a transaction dated Wednesday, July 10th. The shares were sold at an average price of $939.82, for a total value of $197,362,200.00. Following the completion of the sale, the insider now owns 96,943,810 shares of the company’s stock, valued at $91,109,731,514.20. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 1,214,704 shares of company stock valued at $1,066,841,316. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Price Performance

LLY stock traded down $0.31 during midday trading on Monday, reaching $921.81. The company had a trading volume of 2,169,686 shares, compared to its average volume of 3,092,323. The stock has a 50 day moving average price of $878.93 and a 200-day moving average price of $806.28. The company has a debt-to-equity ratio of 1.90, a current ratio of 1.35 and a quick ratio of 1.03. The company has a market capitalization of $876.09 billion, a price-to-earnings ratio of 135.64, a price-to-earnings-growth ratio of 1.81 and a beta of 0.41. Eli Lilly and Company has a 1-year low of $516.57 and a 1-year high of $966.10.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Investors of record on Thursday, August 15th will be paid a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a yield of 0.56%. The ex-dividend date of this dividend is Thursday, August 15th. Eli Lilly and Company’s dividend payout ratio is presently 76.58%.

Analyst Upgrades and Downgrades

LLY has been the topic of several recent analyst reports. Truist Financial restated a “buy” rating and set a $1,000.00 price objective (up from $892.00) on shares of Eli Lilly and Company in a research note on Tuesday, June 25th. Deutsche Bank Aktiengesellschaft upgraded Eli Lilly and Company from a “hold” rating to a “buy” rating and upped their price objective for the company from $725.00 to $1,025.00 in a research note on Monday, August 12th. Berenberg Bank lifted their target price on Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Wednesday, August 14th. Wells Fargo & Company increased their price target on Eli Lilly and Company from $875.00 to $1,000.00 and gave the company an “overweight” rating in a research note on Friday, August 9th. Finally, Guggenheim lifted their price objective on shares of Eli Lilly and Company from $884.00 to $1,030.00 and gave the stock a “buy” rating in a research report on Friday. Two analysts have rated the stock with a hold rating and seventeen have issued a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $956.88.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.